Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Feasibility Study Utilizing IL-17 Blockade to Decrease Risk of Immune Related Adverse Events

NCT07237594 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT07237594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07237594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Feasibility Study Utilizing IL-17 Blockade to Decrease Risk of Immune Related Adverse Events
Lead sponsor
Duke University
Phase
Phase 1
Overall status
Recruiting
Start date
March 12, 2026
Completion date
June 30, 2030
Enrollment
4 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma